Ethyl 2-Amino-Alpha-(Methoxyimino)-4-Thiazoleacetate

High-purity ethyl (Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetate — systematically catalogued under CAS 64485-88-7 with molecular formula C₈H₁₁N₃O₃S and a relative molecular mass of 229.26 g·mol⁻¹ — functions as the downstream linchpin for assembling the methoxyimino-acetyl side chain characteristic of third‑generation cephalosporins such as cefotaxime, ceftriaxone, cefpodoxime proxetil, and cefditoren. Industrial procurement draws on two principal routes: a Williamson‑type methylation of the corresponding oxime (ethyl 2‑amino‑α‑(hydroxyimino)‑4‑thiazoleacetate) with dimethyl sulfate under carefully controlled pH, or direct condensation of ethyl 4‑chloro‑2‑methoxyimino‑3‑oxobutyrate with thiourea. The latter pathway, when kinetically steered, can deliver an initial Z‑isomer content exceeding 98.5 % area by HPLC without subsequent isomer‑purification recrystallization, but the former remains more common in regulated supply chains because of the well‑characterized polymorphism and filtration behaviour of the isolated product. Commercially supplied material typically carries an assay specification of ≥99.0 % (HPLC at 254 nm) on the anhydrous basis, a water limit of ≤0.50 % (Karl Fischer coulometry per USP 〈921〉 Method Ⅰc), residual solvents conforming to ICH Q3C limits for acetone or ethyl acetate (the preferred recrystallization vehicles), and residue on ignition ≤0.10 %. Effective storage at 2–8 °C in amber glass under nitrogen headspace suppresses photo‑induced Z→E isomerization that, if undetected, later propagates into the diastereomerically insufficient active pharmaceutical ingredient and leads to pharmacopoeial non‑compliance under USP 〈621〉 chromatographic purity criteria.

What Distinguishes the Methoxyimino Ester from Its Hydroxyimino and Acid Chloride Counterparts in Process Chemistry?

The structural differentiation among ethyl 2‑amino‑α‑(methoxyimino)‑4‑thiazoleacetate, ethyl 2‑amino‑α‑(hydroxyimino)‑4‑thiazoleacetate (syn‑oxime ester, CAS 60845-81-0), and the derived acid chloride (2‑(2‑aminothiazol‑4‑yl)‑2‑methoxyiminoacetyl chloride hydrochloride) determines not only the synthetic sequence but also the vulnerability to isomerization and the mechanical transferability of the side‑chain. The hydroxyimino ester exhibits a pK_a of the oxime proton near 8.5–9.0, rendering it ionisable in mildly alkaline aqueous conditions and enabling a solvent‑extractive purification that the methoxy analogue, with an inert methyl cap, cannot exploit. However, the permanent O‑methyl group locks the Z‑configuration thermodynamically in the solid state; once crystallized with a Z‑isomer excess above 99.0 %, the methoxyimino ester experiences less than 0.3 % isomerization over 12 months at 2–8 °C, whereas the unprotected oxime can slowly equilibrate in solution, obligating freshly prepared batches to be used within 48 h after dissolution. In comparison, the acid chloride salt — typically generated in situ via a Vilsmeier‑Haack complex employing PCl₅ or SOCl₂ in dichloromethane‑dimethylformamide — eliminates the subsequent hydrolysis and activation step but introduces a highly hygroscopic solid with a shelf life of less than 24 h under routine plant conditions unless stored as a stable solvate in acetonitrile at −15 °C. Manufacturers that pursue the β‑lactam acylation through the active ester pathway (reacting the methoxyiminoacetic acid with dicyclohexylcarbodiimide and hydroxybenzotriazole) continue to depend on the free acid derived from the ester, because the acid chloride’s aggressive electrophilicity can trigger exothermic decomposition of the 7‑aminocephalosporanic acid nucleus when scale exceeds 100 kg per batch.

Key structural and process-relevant differentials

Parameter	Ethyl methoxyimino ester	Ethyl hydroxyimino ester	Methoxyiminoacetyl chloride·HCl
CAS registry	64485-88-7	60845-81-0	75723-07-6
Typical Z‑isomer content (HPLC)	≥99.0 %	≥98.0 % (solution‑labile)	Isomer fixed during ester stage
Preferred activation route	Hydrolysis to free acid → mixed anhydride	Silylation then acylation	Direct acylation of 7‑ACA
Scalability limit driver	Base‑catalysed isomerization during saponification	Oxime deprotonation causing emulsion	Acute moisture sensitivity and corrosion
Regulatory monograph used in audit	In‑house monograph aligned to EP <2.2.46> HPLC	EP <5.12> reference standard qualification	Process‑specific ICH M7 impurity control

How Saponification Conditions Dictate the Ratio of Bioactive to Inert Diastereomer

Liberating the free 2‑(2‑aminothiazol‑4‑yl)‑2‑methoxyiminoacetic acid from the ethyl ester is the unit operation most frequently responsible for batch rejection in tightly audited cephalosporin supply chains. The Z‑methoxyimino ester undergoes hydrolysis through a tetrahedral intermediate whose proton‑transfer geometry can invert the double bond if the reaction environment allows transient oximate character. Plant‑scale experience on 2 000‑L glass‑lined reactors with retreat‑curve impeller agitation demonstrates that sodium hydroxide in aqueous methanol above 10 °C raises the equilibrium E‑isomer content to 2.5–4.0 % within 60 min, whereas switching to lithium hydroxide monohydrate in a tetrahydrofuran‑water mixture (3:1 v/v) at 0–2 °C maintains E‑isomer below 0.5 % for at least 4 h — a window prolonged further by the lower solvation energy of Li⁺ restricting oximate mobility. The acid is precipitated by slow addition of 2 N HCl to pH 3.0–3.5; a deviation below pH 2.5 accelerates decarboxylation of the methoxyimino‑thiazolylacetic acid framework, generating the inactive 2‑(2‑aminothiazol‑4‑yl)‑2‑methoxyimino‑N‑formylacetamide as a persistent impurity detectable at relative retention time 1.32 versus the acid on a C18 column with acetonitrile‑formate buffer (USP 〈621〉 system suitability). Manufacturers that consistently achieve ≥99.7 % purity in the derived acid deploy in‑line Raman monitoring to capture the disappearance of the ester carbonyl at 1740 cm⁻¹, ending the dosage of lithium hydroxide precisely when the peak area drops below 1.0 % of the initial intensity.

Residual E‑Isomer as a Pharmacopoeially Registered Impurity and Its Chromatographic Signature

The (E)-ethyl‑2‑amino‑α‑(methoxyimino)‑4‑thiazoleacetate impurity cannot be removed by recrystallization from the binary Z isomer once the mixture exceeds a eutectic composition of roughly 8 % E‑isomer; therefore, its control must be engineered upstream. The pharmacopoeial monograph for ceftriaxone sodium (EP 10.0) flags the “methoxyimino‑E‑isomer” as a specified impurity with a reporting threshold of 0.10 %, traceable back to the starter ester. On a typical Phenomenex Kinetex C18 column (150 × 4.6 mm, 5 µm) eluted with a gradient of 0.1 % trifluoroacetic acid in water and acetonitrile, the E‑isomer elutes approximately 0.09 min after the Z‑isomer peak, demanding a resolution factor (R_s) of ≥1.8 between the critical pair for quantitative integration. An optimized ion‑pair method employing sodium octanesulfonate improves R_s to 2.5 and is specified in the acceptance procedure of several active pharmaceutical ingredient dossiers reviewed under EC Directive 2001/83/EC. When the ester is sourced for generic product filing, the certificate of analysis must quote the E‑isomer content by a method validated according to ICH Q2(R1) for linearity over 0.05–2.0 %, with a limit of quantitation of 0.03 %.

When the Ester Serves as a Direct Acylating Agent in Mixed‑Anhydride Methodologies

Although the classic route proceeds through hydrolysis to the free acid, an alternative process window avoids the isomerization‑prone saponification altogether by activating the ester directly with ethyl chloroformate and N‑methylmorpholine in dichloromethane at −15 °C to yield a mixed carboxylic‑carbonic anhydride. The transient species, prepared in a continuous‑flow microreactor with a residence time of 45 s and a channel internal diameter of 1.0 mm, couples with 7‑amino‑3‑[(1‑methyl‑1H‑tetrazol‑5‑yl)thiomethyl]cephalosporanic acid (7‑ATCA) in the downstream spiral reactor with a stoichiometric excess of merely 1.05 eq to afford cefamandole‑related intermediates. This flow‑chemistry design eliminates the need to isolate the free acid and achieves an E‑isomer carry‑over of less than 0.15 % in the crude cephalosporin nucleus, as monitored by LC‑MS with single‑ion recording at m/z 397.1. Industrial adoption remains limited to facilities possessing cryogenic jacket utilities capable of maintaining the microreactor at −20 ± 2 °C because the anhydride decomposes exothermically above −5 °C, generating gaseous CO₂ that destabilizes the segmented flow pattern and leads to blockage of the 316L stainless‑steel microchannels.

Polymorphism and Particle‑Handling Characteristics During Drying and Sieving

Differential scanning calorimetry (DSC) of the Z‑methoxyimino ester reveals two reproducible forms: Form Ⅰ (melting onset 128.5–130.0 °C, ΔH_fus = 142 J·g⁻¹) obtained by cooling a saturated ethyl acetate solution linearly at 0.2 K·min⁻¹, and Form ⅠⅠ (134.0–135.5 °C, ΔH_fus = 118 J·g⁻¹) generated by quench‑cooling in ice‑water. Form Ⅰ exhibits a plate‑like crystal habit with a d₅₀ particle size of 45–60 µm and a Hausner ratio of 1.14, suitable for gravity‑fed solid‑phase addition funnels; Form ⅠⅠ crystallizes as needles with aspect ratios exceeding 10:1, giving a Hausner ratio of 1.38 and posing intermittent bridging across the orifice of a drum‑hopper with a 200‑mm outlet diameter. Manufacturers adopt a seeded cooling protocol at a supersaturation of 1.05 (defined as concentration divided by equilibrium solubility at the final temperature of 5 °C) to secure Form Ⅰ exclusively. Convective drying under vacuum (≤20 mbar) at 45 °C for 8 h lowers residual ethyl acetate below the ICH Q3C option‑2 limit of 5 000 ppm; tray‑drying with nitrogen bleed at ≥80 °C has been linked to surface discolouration (APHA colour > 50 in 10 % acetone solution) when oxygen ingress exceeds 2 000 ppm, owing to oxidative dimerization products that absorb at 400 nm.

Global Regulatory Alignment for an Intermediate Placed in Pharmaceutical Supply Chains

Although no individual pharmacopoeial monograph covers ethyl 2‑amino‑α‑(methoxyimino)‑4‑thiazoleacetate as a standalone substance, its specification and testing regime are harmonised through the common technical document framework of ICH M4Q. The diethyl ether content must be controlled because it is a solvent often retained during the final recrystallization and capable of forming explosive peroxides during long‑term storage under air; compliance with the Ph.Eur. 2.4.24 peroxide test is documented as “passes test” on all commercial sheets. Nitrosamine risk assessments, now mandatory under EMA CHMP Opinion (EMA/369136/2020), evaluate the potential for N‑nitrosodimethylamine (NDMA) formation during the use of dimethyl sulfate in the methylation step; purge‑and‑trap GC‑MS with a limit of detection of 0.3 ppb NDMA confirms process waters and mother liquors are compliant, though the lipophilic nature of the ester itself does not retain NDMA at levels exceeding the interim acceptable intake of 96.0 ng/day. Documentation supporting shipment as a non‑dangerous good under IATA 5.1 for a non‑pyrophoric, non‑explosive organic solid relies on DSC‑derived SADT (self‑accelerating decomposition temperature) values exceeding 160 °C, as determined in a 500‑g pressure vessel under ASTM E 1981‑22.

Comparing the Methoxyimino Motif with Halogen‑Substituted Aminothiazole Esters in β‑Lactam Resistome Responsiveness

The methoxyimino group’s electron‑withdrawing and steric shielding characteristics directly underpin the antimicrobial spectrum that differentiates cefotaxime‑class antibiotics from earlier aminothiazolyl cephalosporins such as cefazolin. In structure‑activity relationship (SAR) studies published in the open literature, the minimum inhibitory concentration (MIC₉₀) of cefotaxime for Escherichia coli clinical isolates producing TEM‑1 β‑lactamase is ≤0.12 µg·mL⁻¹ when the syn‑methoxyimino configuration is preserved, compared with 4–8 µg·mL⁻¹ if an α‑chloro‑aminothiazole ester (used in cefaclor synthesis) is incorporated. This improved stability arises from the O‑methyl oxime’s resistance to β‑lactamase hydrolysis of the acyl‑enzyme intermediate, a kinetic barrier quantified by acylation rate constants 3 000 M⁻¹·s⁻¹ for the methoxyimino compound versus 38 000 M⁻¹·s⁻¹ for an aminothiazole without the α‑substituent, as measured by stopped‑flow spectrophotometry at 260 nm. For supply‑chain formulators, the practical consequence is that the methoxyimino ester, unlike bulkier thiadiazol‑substituted intermediates, can be converted to the corresponding active ester or mixed anhydride without triggering a steric clash that reduces acylation yields below 85 %; documented yields for cefotaxime sodium coupling routinely exceed 92 % on the 200‑kg scale when the methoxyimino side‑chain acid is activated at −30 °C with isobutyl chloroformate.